866-997-4948(US-Canada Toll Free)

Glutamate Receptor Ionotropic NMDA 2B (Glutamate (NMDA) Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Pipeline Review, H1 2018

Published By :

Global Markets Direct

Published Date : Jan 2018

Category :

Pharmaceutical

No. of Pages : 57 Pages

Glutamate Receptor Ionotropic NMDA 2B (Glutamate (NMDA) Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Pipeline Review, H1 2018

Summary

According to the recently published report 'Glutamate Receptor Ionotropic NMDA 2B - Pipeline Review, H1 2018'; Glutamate Receptor Ionotropic NMDA 2B (Glutamate (NMDA) Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) pipeline Target constitutes close to 15 molecules. Out of which approximately 15 molecules are developed by Companies.

Glutamate Receptor Ionotropic NMDA 2B (Glutamate (NMDA) Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Glutamate receptor subunit epsilon-2 or N-methyl D-aspartate receptor subtype 2B (NMDAR2B or NR2B) is a protein encoded by the GRIN2B gene. It is mediated by glycine. It acts as a central mediator for stroke damage. Its phosphorylation at Ser-1303 by DAPK1 enhances synaptic NMDA receptor channel activity inducing injurious Ca2+ influx through them resulting in an irreversible neuronal death.

The report 'Glutamate Receptor Ionotropic NMDA 2B - Pipeline Review, H1 2018' outlays comprehensive information on the Glutamate Receptor Ionotropic NMDA 2B (Glutamate (NMDA) Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Glutamate Receptor Ionotropic NMDA 2B (Glutamate (NMDA) Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 1, 7, 1 and 1 respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular and Dermatology which include indications Major Depressive Disorder, Treatment Resistant Depression, Acute Ischemic Stroke, Autism, Brain Ischemia, Burns, Chronic Pain, Cognitive Impairment Associated With Schizophrenia (CIAS), Depression, Infantile Spasm (West Syndrome), Myocardial Infarction, Neurodegenerative Diseases, Neuropathic Pain, Obsessive-Compulsive Disorder, Subarachnoid Hemorrhage, Traumatic Brain Injury and Traumatic Spinal Cord Injury.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Glutamate Receptor Ionotropic NMDA 2B (Glutamate (NMDA) Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B)
- The report reviews Glutamate Receptor Ionotropic NMDA 2B (Glutamate (NMDA) Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glutamate Receptor Ionotropic NMDA 2B (Glutamate (NMDA) Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glutamate Receptor Ionotropic NMDA 2B (Glutamate (NMDA) Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glutamate Receptor Ionotropic NMDA 2B (Glutamate (NMDA) Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glutamate Receptor Ionotropic NMDA 2B (Glutamate (NMDA) Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glutamate Receptor Ionotropic NMDA 2B (Glutamate (NMDA) Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Glutamate Receptor Ionotropic NMDA 2B (Glutamate (NMDA) Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Overview 6
Glutamate Receptor Ionotropic NMDA 2B (Glutamate (NMDA) Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 11
Glutamate Receptor Ionotropic NMDA 2B (Glutamate (NMDA) Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Therapeutics Assessment 14
Assessment by Mechanism of Action 14
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Glutamate Receptor Ionotropic NMDA 2B (Glutamate (NMDA) Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Companies Involved in Therapeutics Development 19
BioCrea GmbH 19
Bristol-Myers Squibb Co 19
Cadent Therapeutics 20
Cerecor Inc 20
Evotec AG 20
Johnson & Johnson 21
NeurOp Inc 21
Novartis AG 22
Shionogi & Co Ltd 22
UCB SA 23
Glutamate Receptor Ionotropic NMDA 2B (Glutamate (NMDA) Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Drug Profiles 24
BMS-986163 - Drug Profile 24
EVT-100 Series - Drug Profile 25
ifenprodil - Drug Profile 26
JNJ-0808 - Drug Profile 27
Neu-2000 - Drug Profile 28
NP-10679 - Drug Profile 30
NP-11948 - Drug Profile 32
radiprodil - Drug Profile 33
rislenemdaz - Drug Profile 35
Small Molecule to Antagonize NR2B for Depression - Drug Profile 38
Small Molecules to Agonize NMDA2B for Cognitive Impairment Associated with Schizophrenia - Drug Profile 39
Small Molecules to Antagonize GRIN2B for Autism and Obsessive Compulsive Disorders - Drug Profile 41
Small Molecules to Antagonize NMDA Receptor 2B for Major Depressive Disorder and Treatment Resistant Depression - Drug Profile 42
Small Molecules to Antagonize NMDA2B for Chronic Pain - Drug Profile 43
Small Molecules to Antagonize NR2B for Neuropathic Pain - Drug Profile 44
Glutamate Receptor Ionotropic NMDA 2B (Glutamate (NMDA) Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Dormant Products 45
Glutamate Receptor Ionotropic NMDA 2B (Glutamate (NMDA) Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Discontinued Products 46
Glutamate Receptor Ionotropic NMDA 2B (Glutamate (NMDA) Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Product Development Milestones 47
Featured News & Press Releases 47
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 55
Disclaimer 56

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by BioCrea GmbH, H1 2018
Pipeline by Bristol-Myers Squibb Co, H1 2018
Pipeline by Cadent Therapeutics, H1 2018
Pipeline by Cerecor Inc, H1 2018
Pipeline by Evotec AG, H1 2018
Pipeline by Johnson & Johnson, H1 2018
Pipeline by NeurOp Inc, H1 2018
Pipeline by Novartis AG, H1 2018
Pipeline by Shionogi & Co Ltd, H1 2018
Pipeline by UCB SA, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *